-
Journal of the European Academy of... Aug 2021
Topics: Alitretinoin; Cyclosporine; Humans; Methotrexate; Prurigo; Pruritus
PubMed: 33811403
DOI: 10.1111/jdv.17262 -
Clinical and Experimental Dermatology Apr 2017
Topics: Alitretinoin; Antineoplastic Agents; Cell Transformation, Neoplastic; Humans; Ki-1 Antigen; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Tretinoin
PubMed: 28211143
DOI: 10.1111/ced.13046 -
Clinical and Experimental Dermatology Apr 2011Alitretinoin, like all retinoids, is teratogenic, and can only be given to women of childbearing potential if pregnancy is excluded and a strict contraceptive programme... (Randomized Controlled Trial)
Randomized Controlled Trial
BACKGROUND
Alitretinoin, like all retinoids, is teratogenic, and can only be given to women of childbearing potential if pregnancy is excluded and a strict contraceptive programme is followed.
AIM
This study was designed to determine whether alitretinoin in the semen of men treated with alitretinoin poses a teratogenic risk to their female partners.
METHODS
In total, 24 healthy men aged 18-45 years received alitretinoin 20 mg (n = 12) or 40 mg (n = 12), once daily for 14 days. Subjects in the 40 mg dose group provided ejaculate at baseline, on day 1, before and approximately 4 h after dosing on day 2, and at follow-up on study day 21 (± 2).
RESULTS
Alitretinoin and 4-oxo-alitretinoin were detected in 11 of the 12 semen samples. The highest level of alitretinoin in semen was 7.92 ng/mL. Assuming an ejaculate volume of 10 mL, the amount of drug transferred in semen would be about 80 ng, 1/375,000 of a single 30 mg capsule. Complete absorption of 80 ng of alitretinoin from semen, presuming a volume of distribution confined to 5 L of circulating blood in the partner, would lead to an increase in plasma alitretinoin concentration of 0.016 ng/mL, which appears to be negligible compared with measured endogenous plasma levels. Increases in plasma levels of related retinoids are also negligible.
CONCLUSIONS
Alitretinoin in the semen of men receiving up to 40 mg of oral alitretinoin per day is unlikely to be associated with teratogenic risk in their female partners. Barrier contraception is therefore not required for men taking alitretinoin.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Adolescent; Adult; Alitretinoin; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Middle Aged; Risk Assessment; Semen; Tretinoin; Young Adult
PubMed: 21443599
DOI: 10.1111/j.1365-2230.2011.04032.x -
Dermatologic Therapy Sep 2019Frontal fibrosing alopecia (FFA) is an inflammatory disorder characterized by scarring alopecia of the frontotemporal scalp, thinning or loss of facial hair, and facial...
Frontal fibrosing alopecia (FFA) is an inflammatory disorder characterized by scarring alopecia of the frontotemporal scalp, thinning or loss of facial hair, and facial papules. Prompt treatment is essential to prevent permanent hair loss. Although studies have reported the efficacy of oral retinoids (isotretinoin and acitretin) in FFA treatment, a therapeutic role for alitretinoin is known only for lichen planus and not for FFA. Herein, we report a case of FFA accompanied with lichen planus that responded well to treatment with alitretinoin.
Topics: Administration, Oral; Alitretinoin; Alopecia; Biopsy; Dermatologic Agents; Disease Progression; Dose-Response Relationship, Drug; Female; Forehead; Humans; Middle Aged; Scalp
PubMed: 31361931
DOI: 10.1111/dth.13037 -
Clinics in Dermatology 2011Hand dermatitis can cause significant morbidity. It is not only pruritic, painful, and adversely affects manual dexterity, but it is also very visible, resulting in a... (Review)
Review
Hand dermatitis can cause significant morbidity. It is not only pruritic, painful, and adversely affects manual dexterity, but it is also very visible, resulting in a substantial psychosocial and physical impact. The prevalence of hand dermatitis in the general population is 5% to 10%, and it appears to be twice as common in women than in men. Certain occupations predispose workers to hand dermatitis, especially those that require frequent hand washing or exposure to particular substances such as solvents. Hand dermatitis has a significant economic effect on society, and the socioeconomic and psychologic effect for the individual can be catastrophic. The need for effective management of this condition is, therefore, quite clear; however, historically hand dermatitis is difficult to treat. This contribution reviews the various types of hand dermatitis and how best to manage them and examines the role which the recently introduced drug alitretinoin now plays in managing this clinically challenging condition.
Topics: Alitretinoin; Dermatitis, Occupational; Dermatologic Agents; Female; Hand Dermatoses; Humans; Male; Treatment Outcome; Tretinoin
PubMed: 21496734
DOI: 10.1016/j.clindermatol.2010.11.005 -
Dermatologic Therapy Jul 2019
Topics: Adult; Alitretinoin; Chronic Disease; Dermatologic Agents; Eczema; Female; Hand Dermatoses; Humans; Male; Middle Aged; Republic of Korea; Retrospective Studies; Severity of Illness Index; Treatment Outcome
PubMed: 31168895
DOI: 10.1111/dth.12980 -
Clinical and Experimental Dermatology Apr 2011Recent studies have found that alitretinoin can induce clinically significant responses in subjects with severe chronic hand eczema (CHE) unresponsive to topical... (Randomized Controlled Trial)
Randomized Controlled Trial
BACKGROUND
Recent studies have found that alitretinoin can induce clinically significant responses in subjects with severe chronic hand eczema (CHE) unresponsive to topical corticosteroids.
AIMS
To assess the pharmacokinetics (PK), efficacy and safety of alitretinoin 10 or 30 mg once daily.
METHODS
This was a randomized, double-blind study, which enrolled 32 subjects aged 18-75 years with CHE unresponsive to potent topical corticosteroids. Subjects received alitretinoin 10 mg (n = 16) or 30 mg (n = 16) once daily for 12 or 24 weeks. Standard PK variables [area under the curve (AUC) of plasma concentration vs. time, maximum plasma concentration (C(max)), time to maximum plasma concentration (t(max)), elimination half-life (t(1/2)), total systemic clearance (CL/F) and volume of distribution (Vd/F)] were determined for alitretinoin and metabolites. Efficacy was assessed using the Physician's Global Assessment (PGA) scale.
RESULTS
Chronic administration of alitretinoin for up to 24 weeks did not result in accumulation or time-dependent changes in the disposition of alitretinoin. Exposure was found to be proportional to dose. Systemic exposure (AUC) to alitretinoin was proportional to dose for 10 and 30 mg alitretinoin; 62.8% of subjects achieved clear/almost clear hands in the 30 mg group and 12.5% in the 10 mg group. Alitretinoin was well tolerated.
CONCLUSIONS
Chronic administration of alitretinoin for 12-24 weeks did not lead to accumulation or time-dependent changes in drug exposure. Alitretinoin was effective and well tolerated in the treatment of subjects with moderate or severe CHE unresponsive to potent topical corticosteroids.
Topics: Adolescent; Adult; Aged; Alitretinoin; Chronic Disease; Dermatologic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Hand Dermatoses; Humans; Male; Middle Aged; Treatment Outcome; Tretinoin; Young Adult
PubMed: 21443602
DOI: 10.1111/j.1365-2230.2011.04035.x -
The British Journal of Dermatology Sep 2023
Topics: Humans; Alitretinoin; Double-Blind Method; Eczema; Antibodies, Monoclonal, Humanized
PubMed: 37337439
DOI: 10.1093/bjd/ljad199 -
Sub-cellular Biochemistry 2014Retinoid X Receptors (RXR) were initially identified as nuclear receptors binding with stereo-selectivity the vitamin A derivative 9-cis retinoic acid, although the... (Review)
Review
Retinoid X Receptors (RXR) were initially identified as nuclear receptors binding with stereo-selectivity the vitamin A derivative 9-cis retinoic acid, although the relevance of this molecule as endogenous activator of RXRs is still elusive. Importantly, within the nuclear receptor superfamily, RXRs occupy a peculiar place, as they are obligatory partners for a number of other nuclear receptors, thus integrating the corresponding signaling pathways. In this chapter, we describe the structural features allowing RXR to form homo- and heterodimers, and the functional consequences of this unique ability. Furthermore, we discuss the importance of studying RXR activity at a genome-wide level in order to comprehensively address the biological implications of their action that is fundamental to understand to what extent RXRs could be exploited as new therapeutic targets.
Topics: Alitretinoin; Animals; Gene Expression Regulation; Humans; Ligands; Mice; Protein Binding; Protein Isoforms; Protein Multimerization; Protein Structure, Tertiary; Receptors, Retinoic Acid; Response Elements; Retinoid X Receptors; Signal Transduction; Tretinoin
PubMed: 24962882
DOI: 10.1007/978-94-017-9050-5_5 -
Journal of the European Academy of... Oct 2018Trachyonychia can be refractory to conventional treatments including topical, intralesional or systemic corticosteroids, as well as cyclosporine and retinoids....
BACKGROUND
Trachyonychia can be refractory to conventional treatments including topical, intralesional or systemic corticosteroids, as well as cyclosporine and retinoids. Therefore, new treatment options are needed for recalcitrant trachyonychia.
OBJECTIVE
To evaluate the efficacy and safety of oral alitretinoin for idiopathic recalcitrant trachyonychia.
METHODS
A total of 21 adult patients with 210 nails affected by idiopathic recalcitrant trachyonychia were evaluated in this open-label prospective study. All patients took 30 mg of alitretinoin daily for at least 3 months. Clinical outcomes were assessed using the Physician Global Assessment (PGA) scale proposed by Park et al. (degree of roughness: 0, clear; 1, mild; 2, moderate; 3, marked; 4, severe) at baseline and 1, 3 and 6 months after treatment.
RESULTS
After 1, 3 and 6 months of treatment, 74.3% (123/210), 98.1% (206/210) and 99.2% (119/120) of nails showed clinical improvement, respectively; 0% (0/210), 22.9% (48/210) and 69.2% (83/120) were completely free from nail abnormalities. The mean PGA score at baseline was 3.4, decreasing significantly to 2.7, 1.3 and 0.7 at 1, 3 and 6 months following treatment, respectively.
LIMITATIONS
A small number of participants and lack of a control group were limitations.
CONCLUSIONS
For the first time, this study evaluated the efficacy and safety of oral alitretinoin for idiopathic recalcitrant trachyonychia in adults. The results suggest that oral alitretinoin can be a good treatment option for adult patients with recalcitrant trachyonychia.
Topics: Administration, Oral; Adult; Aged; Alitretinoin; Dermatologic Agents; Female; Humans; Male; Middle Aged; Nail Diseases; Prospective Studies; Retreatment; Severity of Illness Index; Treatment Outcome; Young Adult
PubMed: 29704273
DOI: 10.1111/jdv.15024